Ovarian cancer not only has a high incidence but also is a pelvic tumor with a high degree of malignancy. The pathogenetic factors are not fully understood, but studies have shown that they are related to reproductive and genetic factors. Its histological origin is complex, and the most common primary ovarian cancers are adenocarcinoma, plasmacytic or mucinous cystic adenocarcinoma, and endometrioid carcinoma. Because the ovary is located deep in the pelvic cavity, many patients are already in advanced stage when ovarian cancer is discovered, and the tumor has spread and developed ascites or metastasis to other organs, while liver metastasis has a high incidence both in primary ovarian cancer and in patients with recurrent metastasis after ovarian cancer surgery. In fact, pelvic implantation, liver metastasis, spleen metastasis, retroperitoneal lymph node metastasis and vaginal stump metastasis are all common ovarian cancer metastasis sites. At present, in addition to traditional systemic intravenous chemotherapy and radiotherapy, interventional treatment has a place in the treatment of these metastatic sites. Interventional therapy refers to introducing a very thin catheter from the femoral artery in the groin to the tumor blood supply artery, such as hepatic artery, splenic artery, internal pubic artery, etc., under the guidance of large medical imaging equipment, and sometimes it is necessary to use microcatheters to guide the catheter directly to the tumor blood supply artery and inject chemotherapeutic drugs or embolic agents, so that the drugs can act directly on the tumor, and then the drugs are distributed throughout the body, which results in a large local concentration of drugs in the tumor and a small systemic side effect. The local concentration of the drug in the liver of the tumor is high, while the systemic side effects are small; embolic agents can cause ischemic necrosis of the tumor. At present, there are also microspheres with drugs, which can be retained in the tumor blood vessels to reduce the blood supply to the tumor, and at the same time, the drugs can be continuously released in the tumor to achieve the purpose of continuous killing of tumor. Interventional therapy is superior to systemic intravenous drug delivery. Firstly, the drug dosage is less than that of systemic chemotherapy, so the side effects are less. Secondly, interventional embolization can reduce the blood supply to the tumor, and its therapeutic effect cannot be achieved by intravenous drug administration. Drug resistance in ovarian cancer is inevitable and the main reason for treatment failure, but even for patients who have failed traditional treatment, interventional therapy can still be used to control the development of the disease, which is especially applicable to patients with advanced stage, because most patients with liver metastases are already resistant to chemotherapy or have undergone many times of systemic chemotherapy, and their physique is so weak that they cannot tolerate the side effects of chemotherapy again; for patients with advanced stage For patients with advanced metastases, the fundamental treatment is how to reduce pain and improve survival quality. For patients with advanced metastatic tumors, different treatment concepts make interventional therapy the preferred treatment for advanced tumor patients.